United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

lfb biopharmaceuticals ltd - human fibrinogen - powder and solvent for solution for infusion - 1.5gram

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

laboratoire français du fractionnement et des biotechnologies s.a. - human fibrinogen humain 1,5 g - powder and solvent for solution for injection/infusion - 1,5 g - human fibrinogen 1.5 g - fibrinogen, human

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - heparin sodium, quantity: 2000 iu/l - injection, solution - excipient ingredients: water for injections; sodium chloride; citric acid monohydrate; dibasic sodium phosphate dodecahydrate - indications as at 11 july 2003: heparin sodium in 0.9% sodium chloride intravenous infusion is indicated as an anticoagulant in extracorporeal circulation, dialysis procedures, and as an aid in the maintenance of catheter patency.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - heparin sodium, quantity: 1000 iu/l - injection, solution - excipient ingredients: sodium chloride; citric acid monohydrate; dibasic sodium phosphate dodecahydrate; water for injections - indications as at 11 july 2003: heparin sodium in 0.9% sodium chloride intravenous infusion is indicated as an anticoagulant in extracorporeal circulation, dialysis procedures, and as an aid in the maintenance of catheter patency.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - heparin sodium, quantity: 10 iu/ml - injection, solution - excipient ingredients: water for injections; sodium chloride; sodium hydroxide; hydrochloric acid - indications as at 01 june 2001 : maintenance of the patency of intravenous injection devices.

New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) ltd - tenecteplase 30mg (recombinant) - powder for injection - 30 mg - active: tenecteplase 30mg (recombinant) excipient: arginine phosphoric acid polysorbate 20 water for injection - metalyse is indicated for the thrombolytic treatment of the acute phase of myocardial infarction (ami). treatment should be initiated as soon as possible after symptom onset. treatment can be initiated within 12 hours of symptom onset.

New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) ltd - tenecteplase 40mg (recombinant) - powder for injection - 40 mg - active: tenecteplase 40mg (recombinant) excipient: arginine phosphoric acid polysorbate 20 water for injection - metalyse is indicated for the thrombolytic treatment of the acute phase of myocardial infarction (ami). treatment should be initiated as soon as possible after symptom onset. treatment can be initiated within 12 hours of symptom onset.

New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) ltd - tenecteplase 50mg (recombinant) - powder for injection - 50 mg - active: tenecteplase 50mg (recombinant) excipient: arginine phosphoric acid polysorbate 20 water for injection - metalyse is indicated for the thrombolytic treatment of the acute phase of myocardial infarction (ami). treatment should be initiated as soon as possible after symptom onset. treatment can be initiated within 12 hours of symptom onset.